FOLH1 and prostate carcinoma: PSMA-radioligands are, meanwhile, an established theranostic approach with excellent results and less severe side effects for the management of prostate cancer as shown in the VISION study (ClinicalTrials.gov Identifier: NCT03511664) [17,18,26,27].